MBRX News and Press, Moleculin Biotech Inc. From 05/02/23

Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire Preliminary results demonstrate a durable complete response at starting dose level in eld...

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models PR Newswire Sponsored research data presented in a poster presentation at the American Association f...

2023-03-23 14:02:02 ET Moleculin Biotech, Inc. (MBRX) Q4 2022 Earnings Conference Call March 23, 2023 08:30 ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Officer John Paul Waymack - Senior Chief Medical Off...

2023-03-23 13:21:04 ET Moleculin Biotech ( NASDAQ: MBRX ) was trading around -9% on Thursday after its net loss widened from  $6.7M in 2021 to $29M in 2022. The drug developer's pipeline is yet to generate revenue, but Moleculin Biotech "positive and highly encour...

2023-03-23 07:52:36 ET Moleculin Biotech press release ( NASDAQ: MBRX ): FY net loss of $29M As of December 31, 2022, we had cash and cash equivalents of $43.1 million and prepaid expenses and other current assets of $2.5 million. The Company believes that this cash i...

Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update PR Newswire – 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs – Sufficient capital to fund operations...

Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials PR Newswire – Actively recruiting in three Phase 1b /2 clinical trials (with one now in Phase 2) and have re...

2023-03-21 17:35:58 ET Major earnings expected after the bell on Wednesday include: Chewy ( CHWY ) KB Home ( KBH ) Aeva Technologies ( AEVA ) Moleculin Biotech ( MBRX ) For further details see: Notable earnings after Wednesday's close

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 PR Newswire HOUSTON , March 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),...

Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire Presentation with live video webcast on Tuesday, March 14 th at 12:40 PM ET HOUSTON , March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasda...